SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk. METHODOLOGY/PRINCIPAL FINDINGS: This was a Phase 3, double-blind, randomized, placebo-controlled trial. Participants made up to 12 monthly follow-up visits for HIV testing, adverse event reporting, and study product supply. The study was conducted between September 2004 and December 2006 in Lagos and Ibadan, Nigeria, where we enrolled 2153 HIV-negative women at high risk of HIV infection. Participants were randomized 1 ratio 1 to SAVVY or placebo. The effectiveness endpoint was incidence of HIV infection as indicated by detection of HIV antibodies in oral mucosal transudate (rapid test) or blood (ELISA), and confirmed by Western blot or PCR testing. We observed 33 seroconversions (21 in the SAVVY group, 12 in the placebo group). The Kaplan-Meier estimates of the cumulative probability of HIV infection at 12 months were 0.028 in the SAVVY group and 0.015 in the placebo group (2-sided p-value for the log-rank test of treatment effect 0.121). The point estimate of the hazard ratio was 1.7 for SAVVY versus placebo (95% confidence interval 0.9, 3.5). Because of lower-than-expected HIV incidence, we did not observe the required number of HIV infections (66) for adequate power to detect an effect of SAVVY. Follow-up frequencies of adverse events, reproductive tract adverse events, abnormal pelvic examination findings, chlamydial infections and vaginal infections were similar in the study arms. No serious adverse event was attributable to SAVVY use. CONCLUSIONS/SIGNIFICANCE: SAVVY did not reduce the incidence of HIV infection. Although the hazard ratio was higher in the SAVVY than the placebo group, we cannot conclude that there was a harmful treatment effect of SAVVY.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonspecific topical microbicides are ineffective for preventing HIV infection (40–45).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“We calculated Kaplan-Meier estimates [17] of HIV infection probabilities by treatment group, pooled across sites.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755 · cited 1×
“[1] We conducted this study under an IND to the U.”
MethodDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“[14–15] The analysis plan included a blinded assessment of whether additional participants would be needed to observe the required 66 events.”
MethodDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Tshibaka, L. M., Ettiègne-Traoré, V., Uaheowitchai, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11079-8 · Cited by 797 · cited 1×
“[6,7] C31G (SAVVYH) has a potent effect on enveloped HIV in vitro through a mechanism by which it disrupts the outer membrane.”
Kreiss, J. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490040053025 · Cited by 402 · cited 1×
“[6,7] C31G (SAVVYH) has a potent effect on enveloped HIV in vitro through a mechanism by which it disrupts the outer membrane.”
BackgroundRoddy, R. E., Zekeng, L., Ryan, K. A., Tamoufé, U., Weir, S. S., & Wong, E. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390803 · Cited by 366
Cited by
Items 101–200 of 280
del Río, C., & Curran, J. W. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00121-1 · Cited by 26
Microbicide research: current and future directions
Ramjee, G. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833a9f66 · Cited by 24
Topical microbicides and HIV prevention in the female genital tract.
Cottrell, M. L., & Kashuba, A. D. M. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.292 · Cited by 22
“The study authors of the SAVVY efficacy trials cited an overestimation of anticipated HIV acquisition rates, as local HIV incidence rates were estimated based on previous experience rather than directly measured at the study sites.(24,25) An alternative explanation for the low acquisition rates was an undervalued effe…”
BackgroundResultInfluentialKatzen, L. L., Fernández-Romero, J. A., Sarna, A., Murugavel, K. G., Gawarecki, D., Zydowsky, T. M., & Mensch, B. (2011) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e31822e6160 · Cited by 21
Update on microbicide research and development-seeking new HIV prevention tools for women
Mertenskoetter, T., & Kaptur, P. E. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-1-1 · Cited by 22
“Microbicides 2010 – building bridges in HIv Prevention, Pittsburgh, Pa, Usa, May 22-25, 2010, abstract #58.”
Lederman, M. M., Jump, R., Pilch-Cooper, H. A., Root, M. J., & Sieg, S. F. (2008) · Retrovirology · doi:10.1186/1742-4690-5-116 · Cited by 25
“A further trial of another microbicide detergent -SAVVY- nearly doubled the risk of HIV acquisition among recipients (hazard ratio 1.7), but with few events, these differences were not significant (CI = 0.9–3.5) [ 11 ].”
BackgroundInfluentialMacri, R. V., Karlovská, J., Doncel, G. F., Du, X., Maisuria, B. B., Williams, A. A., Sugandhi, E. W., Falkinham, J. O., Esker, A. R., & Gandour, R. D. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.02.055 · Cited by 22
Non-Specific Microbicide Product Development: Then and Now
Romano, J., Robbiani, M., Doncel, G. F., & Moench, T. R. (2012) · Current HIV Research · doi:10.2174/157016212799304625 · Cited by 25
Optical Coherence Tomography Compared With Colposcopy for Assessment of Vaginal Epithelial Damage
Vincent, K. L., Stanberry, L. R., Moench, T. R., Breitkopf, C. R., Loza, M. L., Wei, J., Grady, J. J., Paull, J. R., Motamedi, M., & Rosenthal, S. L. (2011) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e318238f563 · Cited by 21
“83 Non-Hispanic white 9 (45) 4 (40) Hispanic white 8 (40) 3 (30) African American 2 (10) 2 (20) Asian 1 (5) 1 (10) Parity .”
BackgroundAppropriateness of Hydroxyethylcellulose Gel as a Placebo Control in Vaginal Microbicide Trials
Richardson, B. A., Kelly, C., Gita Ramjee, H., Fleming, T. R., Makanani, B., Roberts, S. T., Musara, P., Mkandawire, N., Moench, T. R., Coletti, A., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31828607c5 · Cited by 21
“0% C31G (SAVVY) gel and one assessing Cellulose Sulfate gel, were halted early and reported a trend for a higher rate of HIV incidence in women randomized to the active gel arm.(12,14) The results from HPTN 035 provide additional evidence to suggest that this apparent increased risk of HIV was likely not due to a high…”
ResultWhy Do We Need New Drug Classes for HIV Treatment and Prevention?
Waheed, A. A., & Tachedjian, G. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616999151013124606 · Cited by 24
Sepúlveda‐Crespo, D., de la Mata, F. J., Gómez, R., & Muñoz‐Fernández, M. Á. (2018) · Nanoscale · doi:10.1039/c8nr01664j · Cited by 21
Zalenskaya, I. A., Cerocchi, O. G., Joseph, T. D., Donaghay, M., Schriver, S. D., & Doncel, G. F. (2011) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00964.x · Cited by 22
Zalenskaya, I. A., Joseph, T. D., Bavarva, J. H., Yousefieh, N., Jackson, S. S., Fashemi, T., Yamamoto, H. S., Settlage, R. E., Fichorova, R. N., & Doncel, G. F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128557 · Cited by 22
“Two other microbicide candidates, C31G (Savvy) and cellulose sulfate (CS) which failed in phase III clinical trials also proved to alter the mucosal microenvironment [8,9].”
BackgroundResults of Effectiveness Trials of PRO 2000 Gel: Lessons for Future Microbicide Trials
Karim, S. S. A. (2010) · Future Microbiology · doi:10.2217/fmb.10.29 · Cited by 21
Biomedical HIV prevention research and epidemic control in Thailand: two sides of the same coin
van Griensven, F., Phanuphak, N., & Srithanaviboonchai, K. (2014) · Sexual Health · doi:10.1071/sh13119 · Cited by 19
Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States
Chen, N. E., Meyer, J. P., & Springer, S. A. (2011) · Infectious Disease Reports · doi:10.4081/idr.2011.e6 · Cited by 21
Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro
Lai, B. E., Geonnotti, A. R., DeSoto, M. G., Montefiori, D. C., & Katz, D. F. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.08.006 · Cited by 20
An overview of properties of Amphora (Acidform) contraceptive vaginal gel
Nelson, A. L. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1515197 · Cited by 18
“When it was tested in a comparative randomized trial with N-9, it was as effective as N-9 as a contraceptive, but it lacked the ability to reduce HIV transmission [32,33].”
MethodPoynten, I., Jin, F., Prestage, G., Kaldor, J. M., Kippax, S. C., & Grulich, A. (2010) · HIV Medicine · doi:10.1111/j.1468-1293.2010.00833.x · Cited by 20
Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS
Sk, G., & Vinu, N. (2013) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s39164 · Cited by 19
“Further, its safety was a concern, as several adverse events associated with reproductive tract were reported.(35,36) Sodium lauryl sulfate (Invisible Condom; Université Laval, Quebec, Canada), another surfactant has been shown to disrupt both nonenveloped and enveloped viruses.”
BackgroundOmar, R. F., & Bergeron, M. G. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.05.001 · Cited by 20
Delivering on MPTs: addressing the needs, rising to the challenges and making the opportunities
Malcolm, K. R., & Fetherston, S. (2013) · Contraception · doi:10.1016/j.contraception.2013.06.009 · Cited by 19
Abaasa, A. M., Nash, S., Mayanja, Y., Price, M. A., Fast, P., Kamali, A., Kaleebu, P., & Todd, J. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.02.072 · Cited by 18
“In three microbicides trials in Nigeria [16] and Ghana [17,18] in 2007/8, an HIV incidence of 5 per 100 person years at risk (PYAR) was predicted in the placebo arms of the trial communities.”
BackgroundMind the gap: An empirical study of post‐trial access in HIV biomedical prevention trials
Haire, B. G., & Jordens, C. F. C. (2013) · Developing World Bioethics · doi:10.1111/dewb.12039 · Cited by 21
Topical Microbicides—What's New?
Karim, Q. A., Baxter, C., & Karim, S. S. A. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182986f80 · Cited by 18
The New Public Health and STD/HIV Prevention
Aral, S. O., Fenton, K. A., & Lipshutz, J. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4526-5 · Cited by 37
Microbicides: A new hope for HIV prevention
Sk, G., & Nutan, N. (2011) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.92639 · Cited by 21
“However, C31G failed to demonstrate efficacy and confirmed this surfactant might not be a good microbicide candidate 39 .”
BackgroundAbaasa, A. M., Crook, A. M., Gafos, M., Anywaine, Z., Levin, J. B., Wandiembe, S., Nanoo, A., Nunn, A., McCormack, S., Hayes, R., et al. (2013) · Trials · doi:10.1186/1745-6215-14-33 · Cited by 19
“To date, six candidate microbicides have been found to be ineffective in phase IIb or III clinical trials [4-11].”
BackgroundMethodZani, B., Pienaar, E. D., Oliver, J., & Siegfried, N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028759 · Cited by 19
“with the protocol [25] and low event rate of the outcome of interest [26] were cited as reasons in one trial each.”
BackgroundPredictors of pregnancy in microbicide trials
Halpern, V., Lie, C.-C., Feldblum, P. J., & Damme, L. V. (2010) · Contraception · doi:10.1016/j.contraception.2010.08.018 · Cited by 16
“The admission criteria and study procedures for these trials have been reported in detail elsewhere in accordance with the CONSORT guidelines [2,6,7].”
BackgroundMethodSelf-citationEmpowering women in human immunodeficiency virus prevention
Karim, Q. A., Humphries, H., & STEIN, Z. A. (2012) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2012.01.006 · Cited by 17
A literature analysis of scientific research on gender incongruence in Muslim nations
Taslim, N., Ahmad, S., Rehman, S. U., Alghamdi, A. T., Alkatheri, H. A. H., Iqbal, A., & Jbeen, A. (2022) · Journal of Public Health Research · doi:10.1177/22799036221124054 · Cited by 19
Baptista, M., & Ramalho‐Santos, J. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709790361548 · Cited by 14
“Some clinical trials were already performed [78], but a phase III, double-blind, randomized, placebo-controlled trial in Nigeria was recently rejected, since Savvy did not reduce the incidence of HIV infection [80].”
MethodTopical microbicides for preventing sexually transmitted infections
Obiero, J. A., Ogongo, P., Mwethera, P. G., & Wiysonge, C. S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007961.pub3 · Cited by 17
Advances in the Prevention of Heterosexual Transmission of HIV/AIDS Among Women in the United States
Chen, N. E., Meyer, J. P., & Springer, S. A. (2011) · Infectious Disease Reports · doi:10.4081/idr.2011.2362 · Cited by 16
HIV prevention research: the ecstasy and the agony
Cates, W., & Feldblum, P. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61824-3 · Cited by 15
Self-citationDezzutti, C. S., Richardson‐Harman, N., Rohan, L. C., Marzinke, M. A., Hoesley, C. J., Panther, L., Johnson, S., Nuttall, J. P., Nel, A. M., & Chen, B. A. (2016) · Medicine · doi:10.1097/md.0000000000004174 · Cited by 14
“[19–24] Limitations exist for all of the preclinical testing models as none can fully recapitulate product use by a participant.”
BackgroundHaaland, R. E., Evans‐Strickfaden, T., Holder, A. N., Pau, C., McNicholl, J. M., Chaikummao, S., Chonwattana, W., & Hart, C. E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00452-12 · Cited by 15
“Initial nonspecific microbicides, such as Carraguard, SAVVY, and PRO2000, showed no efficacy for preventing male-to-female sexual transmission of HIV in clinical trials, while the spermicide Nonoxynol-9 was reported to increase susceptibility to HIV infection (13, 17, 21, 26, 28).”
Backgroundthe MDP team, Gafos, M., Pool, R., Mzimela, M. A., Ndlovu, H. B., McCormack, S., & Elford, J. (2013) · AIDS and Behavior · doi:10.1007/s10461-013-0676-9 · Cited by 16
“While a number of microbicide trials have reported the prevalence of intravaginal cleansing at baseline, ranging from 25 to 100 % [23–27], only two specifically measured intravaginal cleansing in relation to sexual activity and only one of these reported on it during follow-up.”
The effect of heterogeneity on HIV prevention trials
Auvert, B., Sitta, R., Zarca, K., Mahiane, S. G., Pretorius, C., & Lissouba, P. (2011) · Clinical Trials · doi:10.1177/1740774511398923 · Cited by 14
“[27] Microbicide High-risk women from the”
D’Cruz, O. J., Qazi, S., Yiv, S. H., & Uckun, F. M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.655422 · Cited by 13
“, nonoxynol-9 (N-9), cellulose sulfate, SAVVY (C31G), Carraguard and PRO-2000) showed no reduction or even an increased risk of acquiring HIV-1 [14-18].”
BackgroundAn African perspective on mucosal immunity and HIV-1
Pala, P., Román, R. G., Gilmour, J. W., & Kaleebu, P. (2009) · Mucosal Immunology · doi:10.1038/mi.2009.23 · Cited by 16
Antiretroviral-based HIV prevention strategies for women
Chirenje, Z. M., Marrazzo, J. M., & Parikh, U. M. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.79 · Cited by 15
Scott, M. E., Wilson, S. S., Cosentino, L. A., Richardson, B. A., Moscicki, A., Hillier, S. L., & Herold, B. C. (2011) · Cytokine · doi:10.1016/j.cyto.2011.06.011 · Cited by 13
“Not only did the earlier products fail to protect against HIV, but several (Nonoxynol-9, C31G [Savvy], and cellulose sulfate) were associated with at least a trend towards higher rates of HIV infection [2–4].”
Antiretroviral drugs for pre-exposure prophylaxis of HIV infection.
Fernández-Montero, J. V., Barreiro, P., del Romero, J., & Soriano, V. (2012) · PubMed · Cited by 15
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis
Karim, S. S. A., Baxter, C., & Karim, Q. A. (2022) · Antiviral Therapy · doi:10.1177/13596535211067589 · Cited by 15
HIV prevention in southern Africa: why we must reassess our strategies?
Katsidzira, L., & Hakim, J. G. (2011) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2011.02807.x · Cited by 14
“…Kamali et al. 2003; Williams et al. 2003; Kaul et al. 2004; Gregson et al. 2007; Padian et al. 2007; Peterson et al. 2007a; Celum et al. 2008, 2009; Feldblum et al. 2008; Halpern et al. 2008; Jewkes et al. 2008; Skoler-Karpoff et al. 2008; Watson-Jones et al. 2008; Abdool Karim et al. 2009b;…”
BackgroundInfluentialMicrobicides for the prevention of sexually transmitted HIV infection
Karim, Q. A., & Baxter, C. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.153 · Cited by 14
Targeting HIV-1 innate immune responses therapeutically
Ellegård, R., Shankar, E. M., & Larsson, M. (2011) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32834970d8 · Cited by 12
Microbicides & their implications in HIV prevention.
Karim, S. S. A., & Baxter, C. (2010) · PubMed Central · Cited by 12
Effectiveness of vaginal microbicides in preventing HIV transmission
Musekiwa, A., Fernando, N. B., & Abariga, S. A. (2020) · Tropical Medicine & International Health · doi:10.1111/tmi.13401 · Cited by 15
“Feldblum 2008 [9] 2004–2006 Nigeria 2153 Sexually active women 18–35 SAVVY Gel (peri-coital) Yes”
BackgroundMethodInfluentialAbaasa, A. M., Mayanja, Y., Asiki, G., Price, M. A., Fast, P., Ruzagira, E., Kaleebu, P., & Todd, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-86539-x · Cited by 12
Mansoor, L. E., Karim, Q. A., Mngadi, K. T., Dlamini, S., Montague, C. T., Nkomonde, N., Mvandaba, N., Baxter, C., Gengiah, T. N., Samsunder, N., et al. (2014) · Trials · doi:10.1186/1745-6215-15-496 · Cited by 13
“Most of the candidate microbicides that have been tested in late stage prevention trials have not shown protection against HIV infection [15-17,20,23,24], and some products were even potentially harmful [18,19,23].”
Abdel‐Motal, U. M., Harbison, C., Han, T., Pudney, J. A., Anderson, D. J., Zhu, Q. K., Westmoreland, S. V., & Marasco, W. A. (2014) · Gene Therapy · doi:10.1038/gt.2014.56 · Cited by 13
Graham, S. M., Shah, P. S., Aesch, Z. C.-V., Beyene, J., & Bayoumi, A. M. (2009) · HIV Clinical Trials · doi:10.1310/hct1006-413 · Cited by 14
Microbicides for HIV prevention
Ramjee, G. (2011) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.92638 · Cited by 16
“Results of later trials conducted using another surfactant SAVVY (C31G) were compromised by lower than expected HIV incidence in the trial populations, and no firm conclusions on the ability of the product to affect the acquisition of HIV could be reached 25,26 .”
ResultFriedland, B., Stoner, M. C. D., Chau, M. M., Plagianos, M. G., Govender, S. N., Morar, N. S., Altini, L., Skoler-Karpoff, S., Ahmed, K., Ramjee, G., et al. (2015) · AIDS and Behavior · doi:10.1007/s10461-015-1123-x · Cited by 14
“Large-scale trials of Savvy [3, 4], Carraguard [5], Pro-2000 gel [6, 7] and BufferGel [6] found no effect on HIV incidence.”
BackgroundTargeting Cellular Cofactors in HIV Therapy
Dürr, R., Keppler, O. T., Christ, F., Crespan, E., Garbelli, A., Maga, G., & Dietrich, U. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_45 · Cited by 12
Laurie, C., Tota, J. E., El‐Zein, M., Tellier, P., Coutlée, F., Burchell, A. N., & Franco, E. L. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106560 · Cited by 10
Barrier Methods for Human Immunodeficiency Virus Prevention
Eaton, E., & Hoesley, C. J. (2014) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.08.006 · Cited by 14
Estimating contraceptive efficacy: the case of spermicides
Raymond, E. G., Trussell, J., Weaver, M. A., & Reeves, M. F. (2012) · Contraception · doi:10.1016/j.contraception.2012.06.014 · Cited by 11
“[16] C31G Inert gel 2153 36 38 Karim et al.”
Miller, L., Morar, N. S., Kapiga, S., Ramjee, G., & Hayes, R. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002463 · Cited by 12
Why We Don’t Have An HIV Vaccine, And How We Can Develop One
Harris, J. E. (2009) · Health Affairs · doi:10.1377/hlthaff.28.6.1642 · Cited by 13
Barriers and Facilitators of Adherence in User-Dependent HIV Prevention Trials, a Systematic Review
Ambia, J. (2013) · International STD Research & Reviews · doi:10.9734/isrr/2013/3531 · Cited by 11
“Twenty trials enrolled HIV negative participants [4–13,15–17,21,24–29] and four enrolled both HIV negative and HIV positive participants [14,20,22,23].”
BackgroundMethodInfluentialAdvances in HIV Microbicide Development
Olsen, J. S., Easterhoff, D., & Dewhurst, S. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.153 · Cited by 13
“Clinical trials of another surfactant, C3IG (Savvy), were halted when an unexpectedly low rate of HIV infection in the study population made it nearly impossible to achieve statistically significant results [73].”
ResultThe Safety, Persistence, and Acceptability of an Antiretroviral Microbicide Candidate UC781
Bunge, K. E., Macio, I. S., Meyn, L. A., Noguchi, L., Parniak, M. A., Schwartz, J. L., Moncla, B. J., & Hillier, S. L. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182575914 · Cited by 11
- Microbicide Formulation Development: Scale-Up, Affordability, and Intellectual Property Issues
das Neves, J., & Sarmento, B. (2014) · doi:10.1201/b17559-17 · Cited by 11
Musekiwa, A., Muchiri, E., Manda, S., & Mwambi, H. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077014 · Cited by 10
“2004-2006 SAVVY (C31G) Gel FHI SAVVY Trial/ Nigeria [12] Nigeria High Risk Women”
BackgroundUckun, F. M., Cahn, P. E., Qazi, S., & D’Cruz, O. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.664635 · Cited by 13
“Early strategies to prevent the spread of sexual transmission of HIV-1 with first-generation topical antiviral agents led to the failure of 11 clinical trials with 6 microbicide candidates, nonoxynol-9 [5-8], SAVVY /C31G [9,10], cellulose sulfate [11-14], Carraguard /PC-515 [15], PRO 2000 [16,17] and BufferGel [17].”
BackgroundContraception use and effectiveness among women in a trial of the diaphragm for HIV prevention
Blanchard, K., Bostrom, A., Montgomery, E., van der Straten, A., Lince-Deroche, N., de Bruyn, G., Grossman, D., Chipato, T., Gita Ramjee, H., & PADIAN, N. S. (2011) · Contraception · doi:10.1016/j.contraception.2010.10.018 · Cited by 10
“Other HIV prevention trials have reported high rates of pregnancy: between 16 and 64 per 100 woman-years [21] and in some trials up to a quarter of participants became pregnant [22].”
BackgroundHaire, B. G. (2012) · Journal of Medical Ethics · doi:10.1136/medethics-2012-100936 · Cited by 11
Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials
Karim, S. S. A., & Baxter, C. (2013) · Current topics in microbiology and immunology · doi:10.1007/82_2013_330 · Cited by 15
What predicts non-retention in microbicide trials?
Feldblum, P. J., Halpern, V., Lie, C.-C., Obunge, O., Ogunsola, F. T., Ampofo, W., & Opoku, K. B. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.03.008 · Cited by 9
“[3–6] All four trials were approved by ethical committees of the participating institutions, and of FHI or CONRAD, and all participants signed written informed consent forms before screening and enrollment.”
BackgroundSelf-citationKomatsu, T. (2010) · InTech eBooks · doi:10.5772/8133 · Cited by 12
Current and future microbicide approaches aimed at preventing HIV infection in women
Pozzetto, B., Delézay, O., Gagneux‐Brunon, A., Hamzeh‐Cognasse, H., Lucht, F., & Bourlet, T. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.173 · Cited by 9
Wayengera, M., Kajumbula, H., & Byarugaba, W. (2008) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-5-18 · Cited by 8
Topical Prophylaxis for HIV Prevention in Women: Becoming a Reality
Verma, N. A., Lee, A. C., Herold, B. C., & Keller, M. J. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0075-7 · Cited by 10
Karim, Q. A., Baxter, C., & Karim, S. S. A. (2014) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12843 · Cited by 10
Jensen, J. T. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.06.055 · Cited by 7
Saïdi, H., Jenabian, M.-A., & Bélec, L. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0049 · Cited by 9
“The recent disappointing failure of large-scale vaccines 13 and theneedtoimprovemicrobicideefficiency 14–17 revealedthat major gaps in basic science remain to the development of effective microbicide formulations.”
Sifunda, S., Reddy, P. S., Naidoo, N., James, S., & Buchanan, D. A. (2013) · Public Health Ethics · doi:10.1093/phe/pht018 · Cited by 8
Crossover studies with survival outcomes
Buyze, J., & Goetghebeur, E. J. T. (2011) · Statistical Methods in Medical Research · doi:10.1177/0962280211402258 · Cited by 7
Vysloužil, J., Kubová, K., Tkadlečková, V. N., & Vetchý, D. (2019) · Acta Pharmaceutica · doi:10.2478/acph-2019-0030 · Cited by 8
Debating Ethics in HIV Research: Gaps between Policy and Practice in N igeria
Foláyan, M. O., Peterson, K., Haire, B. G., Brown, B. J., Audu, K., Makanjuola, O., Pelemo, B., & Marsh, V. (2014) · Developing World Bioethics · doi:10.1111/dewb.12064 · Cited by 8
Contraception and pregnancy in microbicide trials
Sibeko, S., Cohen, G. M., & Moodley, J. (2012) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2012.01.005 · Cited by 7
Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1
Buckheit, K. W., & Buckheit, R. W. (2012) · Molecular Biology International · doi:10.1155/2012/781305 · Cited by 6
“Hindawi Publishing Corporation Molecular Biology International Volume 2012, Article ID 781305, 12 pages doi:10.1155/2012/781305 Review Article Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1 Karen W. Buckheit and Robert W. Buckheit Jr. Topical Microbicide and STI Re…”
BackgroundInfluentialCalado, R., Mendes, B. B., Conniot, J., Ravasco, J. M. J. M., Sobral, D., Ferreira, C., Ferreira, R., Rodrigues, J. C., Santos, D., Duarte, S., et al. (2024) · Matter · doi:10.1016/j.matt.2024.04.002 · Cited by 7
Jenabian, M.-A., Saïdi, H., Charpentier, C., Bouhlal, H., Schols, D., Balzarini, J. M., Bell, T. W., Vanham, G., & Bélec, L. (2010) · AIDS Research and Therapy · doi:10.1186/1742-6405-7-16 · Cited by 6
“Recent disappointing failure in microbicide clinical trials revealed that major gaps in basic and applied knowledges remain to conceive effective microbicide formulations [ 1- 3 ]. In particular, the failure of phase II/III essays on candidate molecules having crossed successfully all the previous stages of the precli…”
BackgroundA Brief History and Advancement of Contraceptive Multipurpose Prevention Technology (cMPT) Products
Dohadwala, S., Politch, J. A., Barmine, J. H., & Anderson, D. J. (2023) · Open Access Journal of Contraception · doi:10.2147/oajc.s375634 · Cited by 9
“Its efficacy as a microbicide was assessed in a phase III trial, but it did not reduce HIV acquisition.(43) SLS is another surfactant, commonly used in several cosmetic products.”
BackgroundPremature Activation of the HIV RNase H Drives the Virus into Suicide: A Novel Microbicide?
Broecker, F., Andrae, K., & Moelling, K. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0067 · Cited by 7
“Two Phase III clinical trials with another surfactantbased topical microbicide, C31G, were discontinued due to lower-than-expected incidence rates, and showed no efficacy as well.(32,33) Polyanion-based microbicides interact with the positively charged region of the HIV surface protein gp120, thus blocking retroviral…”
Interim data monitoring to enroll higher-risk participants in HIV prevention trials
Halpern, V., Obunge, O., Ogunsola, F. T., Otusanya, S., Umo-Otong, J., Wang, C.-H., & Mehta, N. (2009) · BMC Medical Research Methodology · doi:10.1186/1471-2288-9-44 · Cited by 6
Microbicide safety and effectiveness: an overview of recent clinical trials
Poynten, M., Brown, J., Sovero, M., Millwood, I. Y., & Kaldor, J. M. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32830b0f4c · Cited by 6
Pillay, V., Mashingaidze, F., Choonara, Y. E., du Toit, L. C., Buchmann, E., Maharaj, V. J., Ndesendo, V. M. K., & Kumar, P. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23098 · Cited by 7
Gafos, M., Mzimela, M. A., Ndlovu, H. B., McCormack, S., & McGrath, N. M. (2012) · AIDS Care · doi:10.1080/09540121.2012.722604 · Cited by 10
Chitchian, S., Vincent, K. L., Vargas, G., & Motamedi, M. (2012) · Journal of Biomedical Optics · doi:10.1117/1.jbo.17.11.116004 · Cited by 6
“9 Colposcopic examination and histology of tissue biopsy have been primarily used to assess the effects of microbicides on the integrity of the cervicovaginal epithelium.”
MethodNew biomedical strategies for HIV-1 prevention in women
Baeten, J. M. (2008) · Current Infectious Disease Reports · doi:10.1007/s11908-008-0080-1 · Cited by 10
del Río, C., & Curran, J. W. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00118-1 · Cited by 9
Simian-Human Immunodeficiency Viruses and Their Impact on Non-Human Primate Models for AIDS
Lara, E., Srinivasan, P., & James, M. R. (2012) · InTech eBooks · doi:10.5772/53556 · Cited by 5
“The recent failure and enhanced transmission observed in the first microbicide efficacy trials with nonoxynol-9 and Savvy [193, 194] warrant the need for controlled and careful investigation of topical products in animal models.”
BackgroundNon-Antiretroviral Microbicides for HIV Prevention.
Scott, Y., & Dezzutti, C. S. (2016) · PubMed · Cited by 7
Metadata
- Authors
- Feldblum, P. J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Olayemi, M. O., Wang, L., Nanda, K., & Rountree, W.
- Affiliations
- Family Health International 360 (US)
- Nigerian Institute of Medical Research (NG)
- University of Ibadan (NG)
- Corresponding author
- Feldblum, Paul J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-01-23
- Volume
- 3
- Issue
- 1
- Pages
- e1474
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2190795
- OpenAlex
- W2160780945
- Cited by
- 280
- References
- 28
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 6 · 2015: 14 · 2014: 22 · 2013: 27 · 2012: 42
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- United States Agency for International Development (GPO-A-00-05-00022-00)
- U.S. Food and Drug Administration
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- HIV prevention, vaginal microbicides, HIV seroconversion, HIV incidence, adverse events, chlamydia, vaginal infection
- MeSH terms
- Double-Blind Method, Female, Gels, Humans, Male, Nigeria, Patient Compliance, Placebos, Sexual Behavior, Vagina, HIV Infections, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
